Fill in the required fields to stay up to date with news and announcements about VPRIV.
You have been successfully signed up to receive
communications from Takeda
Click here to unsubscribe
VPRIV DOSING CALCULATOR
- VPRIV is administered as a 60-minute intravenous (IV) infusion once every other week under the supervision of a healthcare professional1
- Always refer to VPRIV’s Prescribing Information, which contains complete dosing and administration information, before administering VPRIV
- Dosage adjustments may be made on an individual basis based on the achievement and maintenance of therapeutic goals1
- VPRIV is dosed according to body weight1
VPRIV dosing calculator
Precise dosing requires patient’s exact weight and an individual calculation by the healthcare professional.
Obtain patient’s weight1
Please enter patient weight in:
Dosage of VPRIV Required
Number of Vials Needed
Obtain patient’s weight1
Calculate the dosage of VPRIV required*:
Patient weight (kg) × 60 U/kg
Calculate the number of vials needed†:
Required VPRIV dosage ÷ 400
Use the exact unit of the required VPRIV dosage—do not round up to the nearest full vial.1
Dispose of unused product.
Patient’s weight = 21 kg
21 kg × 60 U/kg of VPRIV = 1,260 U
1,260 ÷ 400 = 3.15 vials needed
(4 vials are needed to extract 1,260 U of VPRIV)
*Recommended dose of VPRIV is 60 U/kg patient body weight administered once every other week as an
IV infusion.1 This will change if pounds are used in the calculation instead.
†1 vial of VPRIV = 400 Units (U)1
As with any infusion or medical procedure, it is important to assess your patient’s current condition and review their medical history, including any ERT for type 1 Gaucher disease.1 Appropriate medical support should be readily available when VPRIV is administered.1
Check preinfusion vital signs and labs, if required per facility infusion protocol
Review previous infusion notes, if any, to determine if the patient has had infusion reactions to an ERT and to assess any changes since the last visit1
Consider pre-treatment with antihistamines and/or corticosteroids in patients who exhibited symptoms of hypersensitivity associated with prior velaglucerase alfa product infusions1
Notify the patient’s treating physician if the infusion cannot be administered1
IMPORTANT SAFETY INFORMATION
Hypersensitivity reactions, including anaphylaxis, have occurred. The most serious adverse reactions in patients treated with VPRIV were hypersensitivity reactions.
Hypersensitivity reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. Patients were not routinely pre-medicated prior to infusion of VPRIV.